Adagene Inc. (NasdaqGM: ADAG)
Health Care · Biotechnology · CN
$3.82
-4.98% today · +71.1% 1Y
Adagene Inc. (NasdaqGM: ADAG) operates in the Biotechnology industry within the Health Care sector. The company is valued at $269.92M and employs 128 people.
Over the last twelve months the share price has gained 71.1%, trading between 1.30 and 4.85.
Tweenvest scores Adagene Inc. across four factors: quality 31/100, value 80/100, growth 61/100. Its strongest factor is value.
ADAG price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $269.92M
- Revenue (TTM)
- $9.29M
- P/E
- —
- EPS
- -0.39
- Dividend yield
- —
- Beta (5Y)
- 0.57
- 52-week high
- $4.85
- 52-week low
- $1.30
- Avg volume (3M)
- —
- Shares outstanding
- 67.14M
- Employees
- 128
- Next earnings
- —
About Adagene Inc.
Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.
- ISIN
- US0053291078
- Founded
- 2011
- Listed since
- Feb 9, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.